z-logo
Premium
Pulmonary preneoplasia – sequential molecular carcinogenetic events
Author(s) -
Lantuéjoul Sylvie,
Salameire Dimitri,
Salon Caroline,
Brambilla Elisabeth
Publication year - 2009
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2008.03182.x
Subject(s) - atypical adenomatous hyperplasia , pathology , carcinogenesis , dysplasia , adenocarcinoma , lung cancer , carcinoma in situ , hyperplasia , lung , carcinoma , epidermal growth factor receptor , medicine , atypical hyperplasia , cancer research , biology , cancer
Bronchial and bronchioloalveolar carcinogenesis is a multicentric and multistep process, leading to a sequential accumulation of molecular and genetic abnormalities, mainly due to exposure to tobacco carcinogens. Concomitantly, a series of morphological alterations of normal bronchial or bronchioloalveolar epithelium occur, resulting in preneoplastic and then neoplastic lesions. The three pulmonary preneoplastic changes recognized to date in the lung include bronchial squamous dysplasia and in situ carcinoma, preceding invasive squamous cell carcinoma and basaloid carcinoma, atypical adenomatous hyperplasia, a preneoplastic condition of bronchioloalveolar carcinoma, and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, a proposed precursor for carcinoid tumours. Although the gradual accumulation of molecular alterations has been widely investigated in bronchial carcinogenesis, with the aim of determining new biomarkers for early lung cancer detection in high‐risk patients and targeted chemoprevention, lung adenocarcinoma pathogenesis has been only recently highlighted, with the recent discovery of epidermal growth factor receptor mutation pathway in non‐smokers. This review focuses on the current status of molecular pathology in lung cancer and pulmonary preneoplastic conditions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here